Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up. (1st January 2021)

• Record Type: Journal Article
• Authors: Malekzadeh, Parisa; Good, Meghan; Hughes, Marybeth S.
• Is Part Of: International journal of hyperthermia. Volume 38:Number 1(2021)
• Page Start: 326
• Page End: 331
• Publication Date: 2021-01-01
• Subjects: Pediatric -- malignant peritoneal mesothelioma -- cytoreductive surgery -- hyperthermic intraperitoneal chemotherapy; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2020.1858194
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Introduction: Malignant peritoneal mesothelioma (MPM) is a lethal cancer, with approximately 2% of diagnoses occurring in patients less than 40 years of age. The purpose of this study is to report the only long-term follow up and survival of pediatric patients with MPM after multi-modality therapy including cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: We retrospectively investigated a prospectively maintained database including patients <21 years old who underwent CRS and HIPEC from 1994 through 2014. Follow-up information was available through 2019 and is included in this report. Results: Seven young patients underwent CRS and HIPEC. Final histology was epithelioid in all patients. Three patients had received neo-adjuvant systemic chemotherapy. At the time of the operation Peritoneal Cancer Index ranged from 6 to 25. Completeness of cytoreduction score after CRS was 0 in 4 patients, 1 in two patients, and 2 in one patient. Post-operative complications included acute kidney injury ( n = 1), hyperbilirubinemia ( n = 1), bilateral pleural effusions ( n = 1) and pneumothorax requiring chest tube placement ( n = 1). At last available follow-up, 71% of patients ( n = 5) were alive with minimal or no evaluable disease. The remaining two patients had passed away from their disease at 14 and 26 months, respectively, following CRS and HIPEC. Overall survival ranged between 14 and 281 months. Conclusion: Our surgical experience shows that CRS and HIPEC is a feasible and safe treatment option in pediatric patients, potentially improving overall survival.